Core Insights - The news discusses the establishment of Honghu Fusion (Shanghai) Energy Technology Co., Ltd. by Dai Lizhong, the chairman of Shengxiang Biotechnology, highlighting his personal investment in the nuclear fusion sector and his non-involvement in the company's daily operations [1][11]. Company Overview - Shengxiang Biotechnology Co., Ltd. focuses on innovative gene technology, providing integrated diagnostic solutions including in vitro diagnostic reagents, instruments, third-party medical testing services, and biopharmaceuticals. The company is listed on the Sci-Tech Innovation Board and ranks among China's top 100 pharmaceutical companies and the top 100 global medical device companies [3]. - The company has established a global operational network with subsidiaries in major cities across China and key regions worldwide, including the UK, France, the US, Indonesia, the Philippines, and Thailand [3]. Leadership Profile - Dai Lizhong, born in July 1968, is a prominent figure with extensive academic credentials, including degrees from Peking University and Princeton University. He has received numerous awards for his contributions to science and technology, including the National Science and Technology Progress Award and the National Innovation Pioneer Award [6]. Business Developments - Honghu Fusion was officially established on December 7, 2023, with a registered capital of 10 million yuan. The company focuses on engineering and technology research and development, specifically in nuclear power equipment [9]. - The company aims to develop the first high-temperature superconducting stellarator fusion experimental device within four years, positioning itself as a key technology partner in the fusion power industry [11]. Market Position - As of the latest trading session, Shengxiang Biotechnology's stock closed at 21.36 yuan per share, reflecting a 0.9% increase, with a market capitalization of 12.376 billion yuan [12].